University of Kufa Official Website for the University of Kufa
Prof Dr. Ali Jaber Ni’ma and Asst Prof Dr. Abdul-Aal Salman from the Faculty of Medicine – University of Kufa have been awarded a patent by the Central Agency for Standardization and Quality Control under Iraq’s Ministry of Planning for their development of a novel targeted therapy for multiple cancer types.
The patent included the SRA 737 Checkpoint Kinase 1 inhibitor, an innovative treatment designed to combat non-small cell lung cancer (NSCLC) and colorectal cancer. The therapy operates by disrupting cellular checkpoints—critical mechanisms cancer cells exploit to proliferate and divide.
